With rising healthcare costs and the availability of innovative treatments that require greater investment in research and development, United States (US) payers and policymakers have been discussing broader use of economic evaluations for pricing and reimbursement decision-making. Gain knowledge of how economic evaluation, value assessment, and health technology assessments evolved historically in the US and how American payers are currently using such assessments. Learn about the implications of new policy proposals such as allowing for value-based pricing and reimbursement negotiations among public payers. Gain an understanding of the process and evaluation methods used by the Institute for Clinical and Economic Review (ICER), an independent organization that specializes in assessing health technologies in the US. Review differences in economic evaluation methods used by ICER compared with those used by other US value assessment frameworks and evidence typically submitted to US payers. The structure and process of deliberation employed by ICER’s independent panels and US payers’ pharmacy and therapeutic (P&T) committees will be compared.
Study case studies on how interactions between stakeholders (e.g., patient advocacy groups, payers, and manufacturers) and the value assessment group may have impacted the recommendations or decisions. Learn about effective stakeholder communications strategy for assessments of hypothetical new treatments under a variety of review scenarios.
